This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joseph M. Keenan, MD; Cynthia M. Ripsin, MS, MPH; Zhiquan Huang, MD; David J. McCaffrey
University of Minnesota Minneapolis

JAMA. 1994;272(7):513.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The study by Dr McKenney and colleagues¹ is described by the authors as a "well-designed clinical trial." We would concur with that description if the authors would make more explicit the intention of the study, namely, that it was clearly designed to maximize the potential for niacin intolerance and toxicity. Despite their obvious familiarity with the clinical literature, they chose a peculiarly unphysiologic twice-daily dosing schedule. Similarly, they intentionally escalated both the immediate-release (IR) nicotinic acid and sustained-release (SR) nicotinic acid to a total dose of 3000 mg (1500 mg twice daily), whether or not the patient had demonstrated an adequate lipid response at a lower dose. . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Deputy Editor (West), and Margaret A. Winker, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?